Targeting IDH1: Long-Term Efficacy and Tolerance of Ivosidenib in Advanced Chondrosarcoma. (PubMed, Acta Med Port) - Sep 12, 2026 - "These cases highlight the usefulness of ivosidenib as a targeted therapeutic option for patients with metastatic or recurrent unresectable chondrosarcomas with IDH1 mutation. Long-term efficacy with very good tolerance was achieved."
Journal • Oncology • Sarcoma • Solid Tumor • IDH1
|
|
Augusto Moreira; Diana Russo; Joana Mendonça; Mariana Afonso; Miguel Abreu
|